作者
Magdalena Klánová,Ladislav Anděra,Jan Bražina,Jan Švadlenka,Simona Benesova,J. Soukup,Dana Průková,Dana Vejmelková,Radek Jakša,Karel Helman,Petra Vočková,Lucie Latečková,Jan Molinský,Bokang Maswabi,Mahmudul Alam,Roman Kodet,Robert Pytlík,Marek Trněný,Pavel Klener
摘要
<div>Abstract<p><b>Purpose:</b> To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large B-cell lymphoma (DLBCL).</p><p><b>Experimental designs:</b> Immunohistochemical analysis of 105 primary DLBCL samples, and Western blot analysis of 18 DLBCL cell lines for the expression of BCL2, MCL1, and BCL-XL. Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. Analysis of DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL. Immunoprecipitation of MCL1 complexes in selected DLBCL cell lines. Experimental therapy aimed at inhibition of BCL2 and MCL1 using ABT-199 and HHT, single agent, or in combination, <i>in vitro</i> and <i>in vivo</i> on primary cell-based murine xenograft models of DLBCL.</p><p><b>Results:</b> By the pharmacologic targeting of BCL2, MCL1, and BCL-XL, we demonstrated that DLBCL can be divided into BCL2-dependent and MCL1-dependent subgroups with a less pronounced role left for BCL-XL. Derived DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL, as well as the immunoprecipitation experiments, which analyzed MCL1 protein complexes, confirmed these findings at the molecular level. We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines. The marked cytotoxic synergy between ABT-199 and HHT was also confirmed <i>in vivo</i> using primary cell-based murine xenograft models of DLBCL.</p><p><b>Conclusions:</b> As homoharringtonine is a clinically approved antileukemia drug, and ABT-199 is in advanced phases of diverse clinical trials, our data might have direct implications for novel concepts of early clinical trials in patients with aggressive DLBCL. <i>Clin Cancer Res; 22(5); 1138–49. ©2015 AACR</i>.</p></div>